Phathom Pharmaceuticals posted a remarkable 216.9% revenue increase in 2025 driven by pipeline maturation and commercialization progress, yet the company remains unprofitable with a sizable net loss of $221 million. Operational improvements have narrowed losses, reflecting some efficiency gains amidst sustained R&D investment. A January 2026 equity offering bolstered liquidity to $130 million, extending the runway for ongoing development, notably in eosinophilic esophagitis and GERD indications. Leadership changes signal strategic recalibrations as the firm navigates clinical risks and regulatory hurdles typical of the biopharma sector.